ArticleParasites & vectors2025
Fluralaner injectable suspension (Bravecto® injectable) for dogs remains effective against Ixodes ricinus infestations for one-year.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of efficacy and pharmacokinetics of novel fluralaner tablet formulation (WellPet™) in dogs.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTick-borne pathogens are emerging in many regions worldwide with seasonal transmission often shifting to year-round transmission in temperate climatic zones due to climate change. This situation makes year-round protection against ticks advisable. The objective of the study was to confirm the efficacy of a single injection of fluralaner against Ixodes ricinus ticks for up to 56 weeks.
methodsThe study was a single-site, blinded, negative controlled, randomized efficacy study conducted with 20 female dogs. Dogs were randomized into two groups based on tick counts at pre-infestation. Dogs were infested with approximately 45 I. ricinus female ticks plus 5 male ticks at 17 time points over a year. Bravecto
resultsThe tick infestation per infestation day recorded from individual dogs in the negative control group ranged from 0 to 58. At each counting time point, at least seven dogs in the negative control group were infested with ≥ 25% of the ticks placed on them, indicating an adequate tick infestation and a sufficient tick challenge at each time point. The IVP was well tolerated in all dogs. Significantly fewer (p < 0.0001) live attached ticks were recorded from the IVP treated group compared to the control group at each time point. Based on arithmetic means of live attached tick counts, the IVP was 94.97% effective 7 days after administration. Persistent efficacy over one year following IVP administration was confirmed. The treatment efficacy after 12 and 13 months was 99.16% and 96.22%, respectively.
conclusionsBased on the significant reduction in mean live attached I. ricinus counts compared to the negative control group, efficacy based on arithmetic mean ≥ 90%, and adequacy of infestation in the control dogs, the IVP was effective against existing and new I. ricinus tick infestations for up to 394 days following administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.